As new biological therapies continue to be developed, the market has seen an increased need for innovation. Demand  has grown for improved operational efficiency and achieving greater quality and cost reductions in manufacturing processes. Christian Dunne at ChargePoint Technology shows how one of the key challenges facing biopharma manufacturers is eliminating the risk of contamination, which requires effective containment strategies and monitoring of critical manufacturing processes.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/02/Split-Butterfly-Valve-Technology-and-Eradicating.pdf” width=”100%” height=”900px” style=”border:0;”]